

Global Conjugate Vaccine Market Report and Forecast 2023-2031

Market Report | 2023-04-27 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Conjugate Vaccine Market Report and Forecast 2023-2031

Global Conjugate Vaccine Market Outlook

The global conjugate vaccine market size attained a value of USD 16 billion in 2022. The market is anticipated to grow at a CAGR of 11% during the forecast period of 2023-2031 to attain a value of USD 40.9 billion by 2031.

Conjugate Vaccine Market: Introduction

A conjugate vaccine is a type of vaccine that is created by linking a protein or polysaccharide from a disease-causing bacterium or virus to a carrier molecule. This process creates a new molecule that the body's immune system recognizes as foreign and mounts an immune response against it. Conjugate vaccines are used to prevent bacterial infections, particularly in children, and are known to be highly effective.

The primary use of conjugate vaccines is to prevent bacterial infections caused by bacteria that have a polysaccharide capsule. These bacteria are difficult for the immune system to recognize and attack because they are coated with a polysaccharide layer that the immune system does not recognize as foreign. However, when the polysaccharide is linked to a carrier protein, the immune system recognizes it as a foreign invader and produces an immune response against it.

Some examples of bacterial infections that can be prevented with conjugate vaccines include meningitis, pneumonia, and sepsis caused by *Streptococcus pneumoniae*, *Haemophilus influenzae* type b (Hib), and *Neisseria meningitidis*. Conjugate vaccines are also used to prevent infections caused by the bacteria that cause diphtheria and tetanus.

Benefits of conjugate vaccines include:

- High efficacy: Conjugate vaccines are highly effective at preventing bacterial infections and have been shown to be more effective than other types of vaccines.
- Long-lasting protection: Conjugate vaccines provide long-lasting protection against bacterial infections, reducing the need for additional doses or boosters.
- Fewer side effects: Conjugate vaccines are known to have fewer side effects than other types of vaccines, making them a safe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and effective option for immunization.

-□Reduced healthcare costs: Conjugate vaccines can help reduce healthcare costs by preventing bacterial infections that require expensive medical treatment, hospitalization, and rehabilitation.

Overall, conjugate vaccines are an effective and safe way to prevent bacterial infections, particularly in children. They provide long-lasting protection, have few side effects, and can help reduce healthcare costs by preventing costly medical treatment. With the development of new conjugate vaccines, the prevention of bacterial infections is likely to continue to improve in the future.

conjugate Vaccine Market Segmentations

The market can be categorised into type, indications, pathogen type, patient type, end user, and region.

Market Breakup by Type

- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccines

Market Breakup by Indications

- Pneumococcal Disease
- Influenza
- Meningococcal Disease
- Diphtheria Tetanus and Pertussis (DTP)
- Others

Market Breakup by Pathogen Type

- Bacterial Conjugate Vaccine
- Viral Conjugate Vaccine
- Combination (Viral and Bacterial)

Market Breakup by Patient type

- Pediatrics
- Adults

Market Breakup by End User

- Hospitals
- Clinics
- Homecare Settings
- Others

Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Conjugate Vaccine Market Scenario

The global market for conjugate vaccine is a growing segment of the pharmaceutical industry, driven by increasing demand for effective vaccines to prevent bacterial infections. Conjugate vaccines are used to prevent bacterial infections caused by bacteria that have a polysaccharide capsule. They are particularly effective in preventing infections in children, and are used to prevent diseases such as meningitis, pneumonia, and sepsis caused by *Streptococcus pneumoniae*, *Haemophilus influenzae* type b (Hib), and *Neisseria meningitidis*.

The market for conjugate vaccines is expected to continue to grow at a steady pace, driven by several factors, including increasing awareness about the importance of vaccination, the development of new and innovative vaccines, and the increasing adoption of vaccines in emerging markets.

North America is the largest market for conjugate vaccines, owing to the high prevalence of bacterial infections and well-established healthcare infrastructure in the region. However, the Asia Pacific region is expected to witness significant growth in the coming years, driven by the increasing focus on healthcare development and rising demand for cost-effective medical devices. Countries like China and India are expected to be major contributors to this growth due to their large populations and increasing healthcare spending.

The market for conjugate vaccines is highly competitive, with many players offering a wide range of products to cater to the diverse needs of healthcare providers and patients. Some of the key players in the market include Pfizer, Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, and Novartis International AG.

Overall, the conjugate vaccine market is expected to continue to grow at a steady pace, driven by the increasing demand for safe and effective healthcare delivery. With increasing awareness about the importance of vaccination and the development of new and innovative vaccines, the adoption of conjugate vaccines is likely to increase in the coming years, further fuelling the growth of the market.

Key Players in the Global Conjugate Vaccine Market

The report gives an in-depth analysis of the key players involved in the conjugate vaccine market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Merck & Co., Inc.
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Pfizer Inc.
- Sanofi
- Bharat Biotech
- Biological E
- GlaxoSmithKline plc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [] Astellas Pharma Inc.
- [] AstraZeneca
- [] SutroVax Inc.
- [] CSL Limited
- [] Bavarian Nordic
- [] Emergent BioSolutions Inc.
- [] Valneva SE
- [] Moderna, Inc.
- [] Novavax
- [] Johnson & Johnson Services, Inc.
- [] Themis Bioscience GmbH
- [] B. Braun Melsungen AG

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Conjugate Vaccines Market Overview
 - 3.1 Global Conjugate Vaccines Market Historical Value (2016-2022)
 - 3.2 Global Conjugate Vaccines Market Forecast Value (2023-2031)
- 4 Global Conjugate Vaccines Market Landscape
 - 4.1 Global Conjugate Vaccines Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Conjugate Vaccines Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Indications
 - 4.2.3 Analysis by Pathogen Type
- 5 Global Conjugate Vaccines Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Conjugate Vaccines Market Segmentation
 - 6.1 Global Conjugate Vaccines Market by Type
 - 6.1.1 Market Overview
 - 6.1.2 Monovalent Conjugate Vaccines
 - 6.1.3 Multivalent Conjugate Vaccines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 Global Conjugate Vaccines Market by Indications
 - 6.2.1 Market Overview
 - 6.2.2 Pneumococcal Disease
 - 6.2.3 Influenza
 - 6.2.4 Meningococcal Disease
 - 6.2.5 Diphtheria Tetanus and Pertussis (DTP)
 - 6.2.6 Others
- 6.3 Global Conjugate Vaccines Market by Pathogen Type
 - 6.3.1 Market Overview
 - 6.3.2 Bacterial Conjugate Vaccine
 - 6.3.3 Viral Conjugate Vaccine
 - 6.3.4 Combination (Viral and Bacterial)
- 6.4 Global Conjugate Vaccines Market by Patient Type
 - 6.4.1 Market Overview
 - 6.4.2 Pediatrics
 - 6.4.3 Adults
- 6.5 Global Conjugate Vaccines Market by End User
 - 6.5.1 Market Overview
 - 6.5.2 Hospitals
 - 6.5.3 Clinics
 - 6.5.4 Homecare Settings
 - 6.5.5 Others
- 6.6 Global Conjugate Vaccines Market by Region
 - 6.6.1 Market Overview
 - 6.6.2 North America
 - 6.6.3 Europe
 - 6.6.4 Asia Pacific
 - 6.6.5 Latin America
 - 6.6.6 Middle East and Africa
- 7 North America Conjugate Vaccines Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Conjugate Vaccines Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Conjugate Vaccines Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.7 Others
- 10 Latin America Conjugate Vaccines Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Conjugate Vaccines Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.4 Analysis by Geography
- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.1.1 US FDA
 - 17.1.2 EU EMA
 - 17.1.3 INDIA CDSCO
 - 17.1.4 JAPAN PMDA
 - 17.1.5 Others
- 18 Supplier Landscape
 - 18.1 Merck & Co., Inc.
 - 18.1.1 Financial Analysis
 - 18.1.2 Product Portfolio
 - 18.1.3 Demographic Reach and Achievements
 - 18.1.4 Mergers and Acquisitions
 - 18.1.5 Certifications
 - 18.2 Novartis AG
 - 18.2.1 Financial Analysis
 - 18.2.2 Product Portfolio
 - 18.2.3 Demographic Reach and Achievements
 - 18.2.4 Mergers and Acquisitions
 - 18.2.5 Certifications
 - 18.3 Serum Institute of India Pvt. Ltd.
 - 18.3.1 Financial Analysis
 - 18.3.2 Product Portfolio
 - 18.3.3 Demographic Reach and Achievements
 - 18.3.4 Mergers and Acquisitions
 - 18.3.5 Certifications
 - 18.4 Pfizer Inc.
 - 18.4.1 Financial Analysis
 - 18.4.2 Product Portfolio
 - 18.4.3 Demographic Reach and Achievements
 - 18.4.4 Mergers and Acquisitions
 - 18.4.5 Certifications
 - 18.5 Sanofi
 - 18.5.1 Financial Analysis
 - 18.5.2 Product Portfolio
 - 18.5.3 Demographic Reach and Achievements
 - 18.5.4 Mergers and Acquisitions
 - 18.5.5 Certifications
 - 18.6 Bharat Biotech
 - 18.6.1 Financial Analysis
 - 18.6.2 Product Portfolio
 - 18.6.3 Demographic Reach and Achievements
 - 18.6.4 Mergers and Acquisitions
 - 18.6.5 Certifications
 - 18.7 Biological E
 - 18.7.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 GlaxoSmithKline plc.
 - 18.8.1 Financial Analysis
 - 18.8.2 Product Portfolio
 - 18.8.3 Demographic Reach and Achievements
 - 18.8.4 Mergers and Acquisitions
 - 18.8.5 Certifications
- 18.9 Astellas Pharma Inc.
 - 18.9.1 Financial Analysis
 - 18.9.2 Product Portfolio
 - 18.9.3 Demographic Reach and Achievements
 - 18.9.4 Mergers and Acquisitions
 - 18.9.5 Certifications
- 18.10 AstraZeneca
 - 18.10.1 Financial Analysis
 - 18.10.2 Product Portfolio
 - 18.10.3 Demographic Reach and Achievements
 - 18.10.4 Mergers and Acquisitions
 - 18.10.5 Certifications
- 18.11 SutroVax Inc.
 - 18.11.1 Financial Analysis
 - 18.11.2 Product Portfolio
 - 18.11.3 Demographic Reach and Achievements
 - 18.11.4 Mergers and Acquisitions
 - 18.11.5 Certifications
- 18.12 CSL Limited
 - 18.12.1 Financial Analysis
 - 18.12.2 Product Portfolio
 - 18.12.3 Demographic Reach and Achievements
 - 18.12.4 Mergers and Acquisitions
 - 18.12.5 Certifications
- 18.13 Bavarian Nordic
 - 18.13.1 Financial Analysis
 - 18.13.2 Product Portfolio
 - 18.13.3 Demographic Reach and Achievements
 - 18.13.4 Mergers and Acquisitions
 - 18.13.5 Certifications
- 18.14 Emergent BioSolutions Inc.
 - 18.14.1 Financial Analysis
 - 18.14.2 Product Portfolio
 - 18.14.3 Demographic Reach and Achievements
 - 18.14.4 Mergers and Acquisitions
 - 18.14.5 Certifications
- 18.15 Valneva SE

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.15.1 Financial Analysis
- 18.15.2 Product Portfolio
- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Mergers and Acquisitions
- 18.15.5 Certifications
- 18.16 Moderna, Inc.
 - 18.16.1 Financial Analysis
 - 18.16.2 Product Portfolio
 - 18.16.3 Demographic Reach and Achievements
 - 18.16.4 Mergers and Acquisitions
 - 18.16.5 Certifications
- 18.17 Novavax
 - 18.17.1 Financial Analysis
 - 18.17.2 Product Portfolio
 - 18.17.3 Demographic Reach and Achievements
 - 18.17.4 Mergers and Acquisitions
 - 18.17.5 Certifications
- 18.18 Johnson & Johnson Services, Inc.
 - 18.18.1 Financial Analysis
 - 18.18.2 Product Portfolio
 - 18.18.3 Demographic Reach and Achievements
 - 18.18.4 Mergers and Acquisitions
 - 18.18.5 Certifications
- 18.19 Themis Bioscience GmbH
 - 18.19.1 Financial Analysis
 - 18.19.2 Product Portfolio
 - 18.19.3 Demographic Reach and Achievements
 - 18.19.4 Mergers and Acquisitions
 - 18.19.5 Certifications
- 18.20 B. Braun Melsungen AG
 - 18.20.1 Financial Analysis
 - 18.20.2 Product Portfolio
 - 18.20.3 Demographic Reach and Achievements
 - 18.20.4 Mergers and Acquisitions
 - 18.20.5 Certifications
- 19 Global Conjugate Vaccines Market - Distribution Model (Additional Insight)
 - 19.1 Overview
 - 19.2 Potential Distributors
 - 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
 - 21.1 Very Small Companies
 - 21.2 Small Companies
 - 21.3 Mid-Sized Companies
 - 21.4 Large Companies
 - 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket

Global Conjugate Vaccine Market Report and Forecast 2023-2031

Market Report | 2023-04-27 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com